Myomo (MYO) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 04, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	MYO
Entity Registrant Name	MYOMO INC
Entity Central Index Key	0001369290
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		17,199,710
Entity File Number	001-38109
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Tax Identification Number	47-0944526
Entity Address, Address Line One	One Broadway
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	996-9058
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NYSEAMER
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 4,328,355	$ 6,540,794
Accounts receivable, net	134,006	382,258
Inventories, net	454,379	256,149
Prepaid expenses and other current assets	786,732	695,276
Total Current Assets	5,703,472	7,874,477
Restricted cash	75,000	75,000
Deferred offering costs	133,976	144,582
Equipment, net	170,330	187,513
Total Assets	6,082,778	8,281,572
Current Liabilities:
Accounts payable and other accrued expenses	1,552,307	1,743,427
Derivative liabilities	43,942	3,661
Deferred revenue	2,942	1,990
Customer advance payments	63,567	106,609
Total Current Liabilities	1,662,758	1,855,687
Non-Current Liabilities	1,495
Total Liabilities	1,664,253	1,855,687
Commitments and Contingencies
Stockholders’ Equity:
Common stock par value $0.0001 per share, 100,000,000 shares authorized; 17,189,737 and 12,450,187 shares issued as of September 30, 2019 and December 31, 2018, respectively; and 17,188,929 and 12,449,379 shares outstanding at September 30, 2019 and December 31, 2018, respectively	1,716	1,245
Additional paid-in capital	57,787,751	51,720,630
Accumulated deficit	(53,364,478)	(45,289,526)
Treasury stock, 808 shares at cost	(6,464)	(6,464)
Total Stockholders’ Equity	4,418,525	6,425,885
Total Liabilities and Stockholders’ Equity	$ 6,082,778	$ 8,281,572

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,189,737	12,450,187
Common stock, shares outstanding	17,188,929	12,449,379
Treasury shares at cost	808	808

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenue	$ 606,619	$ 608,981	$ 2,317,034	$ 1,554,529
Cost of revenue	194,375	193,577	621,237	502,103
Gross margin	412,244	415,404	1,695,797	1,052,426
Operating expenses:
Research and development	544,679	449,673	1,615,831	1,309,014
Selling, general and administrative	2,692,613	2,674,160	8,294,153	7,536,802
Total operating expenses	3,237,292	3,123,833	9,909,984	8,845,816
Loss from operations	(2,825,048)	(2,708,429)	(8,214,187)	(7,793,390)
Other expense (income)
Change in fair value of derivative liabilities	(14,536)	(13,310)	(155,955)	(31,278)
Interest (income) and other expense, net	(22,394)	(45,297)	(106,727)	(137,327)
Total other expense (income)	(36,930)	(58,607)	(262,682)	(168,605)
Net loss	$ (2,788,118)	$ (2,649,822)	$ (7,951,505)	$ (7,624,785)
Weighted average number of common shares outstanding:
Basic and diluted	17,158,731	12,415,494	16,412,754	12,244,075
Net loss per share
Basic and diluted	$ (0.16)	$ (0.21)	$ (0.48)	$ (0.62)

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning balance at Dec. 31, 2017	$ 12,445,778	$ 1,114	$ 47,423,915	$ (34,972,787)	$ (6,464)
Beginning balance, shares at Dec. 31, 2017		11,138,859			808
Common stock issued upon vesting of restricted stock units	(63,149)	$ 3	(63,152)
Common stock issued upon vesting of restricted stock units, Shares		31,152
Common stock issued for the exercise of warrants	$ 3,550,490	$ 120	3,550,370
Common stock issued for the exercise of warrants, shares		1,203,556
Restricted stock vested		$ 3	(3)
Restricted stock vested, shares	17,570	32,540
Stock-based compensation	$ 336,355		336,355
Net loss	(2,345,402)			(2,345,402)
Ending balance at Mar. 31, 2018	13,924,072	$ 1,240	51,247,485	(37,318,189)	$ (6,464)
Ending balance, shares at Mar. 31, 2018		12,406,107			808
Beginning balance at Dec. 31, 2017	12,445,778	$ 1,114	47,423,915	(34,972,787)	$ (6,464)
Beginning balance, shares at Dec. 31, 2017		11,138,859			808
Net loss	(7,624,785)
Ending balance at Sep. 30, 2018	8,948,935	$ 1,243	51,551,728	(42,597,572)	$ (6,464)
Ending balance, shares at Sep. 30, 2018		12,435,223			808
Beginning balance at Mar. 31, 2018	13,924,072	$ 1,240	51,247,485	(37,318,189)	$ (6,464)
Beginning balance, shares at Mar. 31, 2018		12,406,107			808
Common stock issued upon vesting of restricted stock units	(5,041)	$ (1)	(5,040)
Common stock issued upon vesting of restricted stock units, Shares		3,934
Exercise of stock options	2		2
Exercise of stock options, shares		1,172
Common stock issued for the exercise of warrants	$ 5,901	$ 1	5,900
Common stock issued for the exercise of warrants, shares		2,000
Restricted stock vested		$ 1	(1)
Restricted stock vested, shares	1,692	937
Stock-based compensation	$ 155,725		155,725
Net loss	(2,629,561)			(2,629,561)
Ending balance at Jun. 30, 2018	11,451,098	$ 1,241	51,404,071	(39,947,750)	$ (6,464)
Ending balance, shares at Jun. 30, 2018		12,414,150			808
Common stock issued upon vesting of restricted stock units	$ (3,222)	$ 1	(3,223)
Common stock issued upon vesting of restricted stock units, Shares		3,971
Restricted stock vested		$ 1	(1)
Restricted stock vested, shares	1,653	17,102
Stock-based compensation	$ 150,881		150,881
Net loss	(2,649,822)			(2,649,822)
Ending balance at Sep. 30, 2018	8,948,935	$ 1,243	51,551,728	(42,597,572)	$ (6,464)
Ending balance, shares at Sep. 30, 2018		12,435,223			808
Beginning balance at Dec. 31, 2018	6,425,885	$ 1,245	51,720,630	(45,289,526)	$ (6,464)
Beginning balance, shares at Dec. 31, 2018		12,449,379			808
Cumulative impact of ASC 606	(123,447)			(123,447)
Proceeds of public offering, net offering costs of $710,572	5,603,829	$ 454	5,603,375
Proceeds from offering costs, shares		4,542,500
Common stock issued upon vesting of restricted stock units	(72,115)	$ 10	(72,125)
Common stock issued upon vesting of restricted stock units, Shares		95,001
Restricted stock vested	$ 1	$ 1
Restricted stock vested, shares	45,459	10,436
Warrants issued as offering costs and recorded as a derivative liability	$ (196,236)		(196,236)
Stock-based compensation	396,325		396,325
Net loss	(2,598,060)			(2,598,060)
Ending balance at Mar. 31, 2019	9,436,182	$ 1,710	57,451,969	(48,011,033)	$ (6,464)
Ending balance, shares at Mar. 31, 2019		17,097,316			808
Beginning balance at Dec. 31, 2018	$ 6,425,885	$ 1,245	51,720,630	(45,289,526)	$ (6,464)
Beginning balance, shares at Dec. 31, 2018		12,449,379			808
Exercise of stock options, shares	9,928
Net loss	$ (7,951,505)
Ending balance at Sep. 30, 2019	4,418,525	$ 1,716	57,787,751	(53,364,478)	$ (6,464)
Ending balance, shares at Sep. 30, 2019		17,188,929			808
Beginning balance at Mar. 31, 2019	9,436,182	$ 1,710	57,451,969	(48,011,033)	$ (6,464)
Beginning balance, shares at Mar. 31, 2019		17,097,316			808
Common stock issued upon vesting of restricted stock units	(6,356)	$ 1	(6,357)
Common stock issued upon vesting of restricted stock units, Shares		22,344
Exercise of stock options	15	$ 1	14
Exercise of stock options, shares		8,854
Restricted stock vested	$ (72)	$ 1	(73)
Restricted stock vested, shares	7,032	10,369
Stock-based compensation	$ 197,028		197,028
Net loss	(2,565,327)			(2,565,327)
Ending balance at Jun. 30, 2019	7,061,470	$ 1,713	57,642,581	(50,576,360)	$ (6,464)
Ending balance, shares at Jun. 30, 2019		17,138,883			808
Common stock issued upon vesting of restricted stock units	(1,779)	$ 3	(1,782)
Common stock issued upon vesting of restricted stock units, Shares		41,837
Exercise of stock options	$ 1		1
Exercise of stock options, shares		1,074
Restricted stock vested, shares	3,015	7,135
Stock-based compensation	$ 146,951		146,951
Net loss	(2,788,118)			(2,788,118)
Ending balance at Sep. 30, 2019	$ 4,418,525	$ 1,716	$ 57,787,751	$ (53,364,478)	$ (6,464)
Ending balance, shares at Sep. 30, 2019		17,188,929			808

Condensed Statement of Change_2

Condensed Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Statement Of Stockholders Equity [Abstract]
Offering cost from sale of stock			$ 710,572
Net withheld for employee taxes	3,015	7,032	45,459	1,653	1,692	17,570

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,951,505)	$ (7,624,785)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation	70,678	48,833
Stock-based compensation	740,304	642,961
Excess and obsolete inventory reserve		26,645
Change in fair value of derivative liabilities	(155,955)	(31,278)
Loss on disposal of asset	2,481
Other non-cash charges	14,634	(16,275)
Changes in operating assets and liabilities:
Accounts receivable	248,252	(39,510)
Inventories	(302,608)	(151,332)
Prepaid expenses and other	(130,268)	(332,591)
Other assets	(2,000)
Accounts payable and other accrued expenses	(191,120)	413,317
Deferred revenue	2,447	(29,284)
Customer advance payments	(43,042)
Net cash used in operating activities	(7,697,702)	(7,093,299)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment	(38,261)	(117,370)
Net cash used in investing activities	(38,261)	(117,370)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of issuance costs		(117,273)
Net settlement of vested restricted stock units to fund related employee statutory tax withholding	(80,321)	(71,412)
Proceeds from exercise of stock options	16	2
Proceeds from exercise of warrants		3,556,391
Proceeds from public offering	5,603,829
Net cash provided by financing activities	5,523,524	3,367,708
Net decrease in cash, cash equivalents and restricted cash	(2,212,439)	(3,842,961)
Cash, cash equivalents and restricted cash, beginning of period	6,615,794	13,011,373
Cash, cash equivalents and restricted cash, end of period	4,403,355	9,168,412
SUPPLEMENTAL DISCLOSURE CASH FLOW INFORMATION
Inventory capitalized as sales demo equipment	17,715	$ 53,178
Issuance of warrants recorded as a derivative liability	$ 196,236

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products to orthotics and prosthetics (O&P) providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, often utilizing the clinical services of O&P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Cambridge, Massachusetts.

Going Concern and Management's

Going Concern and Management's Plan	9 Months Ended
	Sep. 30, 2019
Going Concern And Managements Plan Abstract
Going Concern And Management's Plan	Note 2 — Going Concern and Management’s Plan The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company incurred a net loss of approximately $8.0 million and $7.6 million during the nine months ended September 30, 2019 and 2018, respectively; and had an accumulated deficit of approximately $53.4 million at September 30, 2019. Cash used in operating activities was approximately $7.7 million and $7.1 million for the nine months ended September 30, 2019 and 2018, respectively. In February 2019, the Company completed a follow-on offering of its common stock, generating net proceeds of approximately $5.6 million. The Company does not expect that its existing cash and net proceeds from the offering will be sufficient to fund its operations for the twelve months from the filing date of these financial statements. The ability of the Company to continue as a going concern is dependent upon achieving a profitable level of operations and the ability of the Company to obtain necessary financing to fund ongoing operations. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance of these financial statements. On October 22, 2019, the Company entered into a Note Purchase Agreement, Senior Note and Security Agreement (collectively, the “Term Loan”) with Chicago Venture Partners (the “Lender”). Under the Term Loan, the Company received gross proceeds of $3.0 million,excluding fees and expenses. Including an original issue discount, the Company will repay the Lender $3.3 million. .Management plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern are primarily focused on raising additional capital in order to meet its obligations, repay its debt and execute its business plan by pursuing its product development initiatives and penetrate markets for the sale of its products. Management believes that the Company has access to capital resources through possible public or private equity offerings, exercises of outstanding warrants, debt financings (if approved by the Lender), or other means; however, the Company cannot provide any assurance that it will be able to raise additional capital or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. There can be no assurance the Company will be successful in implementing its plans to alleviate substantial doubt.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Interim Financial Statements The accompanying unaudited condensed financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with GAAP for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2019 and for the nine months ended September 30, 2019 and 2018. The results of operations for the nine months ended September 30, 2019 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2019, or any other period. These condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2018 and 2017, and for the years then ended, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving inventory. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2019 and December 31, 2018. Restricted cash consists of cash deposited with a financial institution as collateral for Company employee credit cards. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed balance sheets that sum to the total of the same amounts shown in the condensed statements of cash flows. September 30, 2019 December 31, 2018 Cash and cash equivalents $ 4,328,355 $ 6,540,794 Restricted cash 75,000 75,000 Total cash, cash equivalents, and restricted cash $ 4,403,355 $ 6,615,794 Accounts Payable and Other Accrued Expenses: September 30, 2019 December 31, 2018 Trade payables $ 346,493 $ 426,727 Accrued compensation and benefits 813,655 1,027,757 Accrued directors fees 23,750 — Accrued warranty costs 65,230 92,000 Accrued professional fees 102,233 44,660 Other 200,946 152,283 $ 1,552,307 $ 1,743,427 Revenue Recognition Adoption of ASC Topic 606, “Revenue from Contracts with Customers” On January 1, 2019, the Company adopted the new accounting standard ASC 606, “Revenue from Contracts with Customers” and all the related amendments (Topic 606) using the modified retrospective method for all contracts not completed as of the date of adoption. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with practical expedient ASC 606-10-65-1-(f)-4, which did not have a material effect on the Company’s assessment of the cumulative effect adjustment Revenues under Topic 606 are required to be recognized either at a “point in time” or “over time,” depending on the facts and circumstances of the arrangement, and are evaluated using a five-step model. The adoption of Topic 606 did not have a material impact on the financial statements at initial implementation. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin on an ongoing basis. The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract 3) Determination of the transaction price, including the constraint on variable consideration 4) Allocation of the transaction price to the performance obligations in the contract 5) Recognition of revenue when, or as, performance obligations are satisfied Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. In certain cases, the Company ships the MyoPro device to O&P providers or directly to patients pending reimbursement from third party payors. As a result of these arrangements, elements of the revenue recognition criteria have not been met upon shipment of the MyoPro. During the three and nine months ended September 30, 2019, the Company recognized revenue of approximately $164,000 from O&P providers or third party payors for which costs related to the completion of the Company’s performance obligations were recorded in a prior period. The Company periodically receives federally-funded grants that requires us to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. As required under Topic 606, grant proceeds are now booked as a reduction in R&D expenses. The Company adopted the accounting standard on a modified retrospective method, and the prior comparative 2018 grant revenue has not been restated for presentation purposes. Grant revenue was previously recognized when persuasive evidence of the arrangement existed, the service had been provided and adherence to specific parameters of the awarded grant were met, the amount was fixed and determinable and collection was reasonably assured. The Company recognized the revenue on a completion of performance basis where no ongoing obligation existed, or ratably over the term if the grant of no specific performance was required. Direct costs related to these grants were reported as a component of research and development costs in the statements of operations except for reimbursable costs which were reported as a component of cost of revenue in the statement of operations. The Company recognized approximately $10,100 and $19,100 of grant income in the three and nine months ended September 30, 2018. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Shipping and handling activities are not considered a contract performance obligation. The Company records shipping and handling costs billed to customers as revenue with offsetting costs recorded as cost of revenue. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had an immaterial amount of deferred revenue as of September 30, 2019. Disaggregated Revenue from Contracts with Customers The following table presents revenue by major source: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2019 2019 Clinical/Medical providers $ 405,914 $ 1,837,667 Direct to patient 200,705 479,367 Total revenue from contracts with customer $ 606,619 $ 2,317,034 Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third party payors. Prior to the implementation of ASC 606, the Company had been accounting for this transaction at the time of shipping to an O&P provider by leaving consigned inventory on the balance sheet until the uncertainty regarding payment had been resolved and by providing a consignment inventory reserve based upon the amounts historically collected under this program. Under ASC 340-40-25, this inventory is expensed as of the date of shipment. For clinical services by O&P providers for which they are paid a fee in conjunction with devices being sold directly to patients and billing their insurance companies directly, the cost of evaluations performed by the O&P providers are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense, with the remaining costs associated with the patient expensed to cost of revenue. The Company recorded a net decrease to opening retained earnings of approximately $123,000 as of January 1, 2019 due to the cumulative impact of adopting Topic 606. The cumulative effect of the changes made to the Company’s consolidated balance sheet for the adoption of Topic 606 were as follows: Selected Balance Sheet Accounts Balance at 12/31/18 Adjustments due to ASC 2014-09 Balance at 1/1/19 Assets Inventories, net $ 256,149 $ (84,635 ) $ 171,514 Prepaid expenses and other 695,276 (38,812 ) 656,464 Stockholders’ Equity Accumulated deficit (45,289,526 ) (123,447 ) (45,412,973 ) Net Loss per Share Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three and nine months ended September 30, 2019 and 2018, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential common shares issuable consist of the following at: September 30, 2019 2018 Stock options 668,785 626,619 Restricted stock units 385,337 43,751 Restricted stock 10,266 48,707 Stock warrants 5,435,287 5,071,887 Total 6,499,675 5,790,964 Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, or ASU 2016-02. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial statements. As an emerging growth company, the Company will delay adoption of ASU 2016-02 until January 1, 2020. Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed in Note 11 herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Note 4 — Inventories Inventories consist of the following at: September 30, 2019 December 31, 2018 Finished goods $ 35,165 $ 46,261 Consigned inventory — 135,635 Parts and components 419,214 149,253 454,379 331,149 Less: excess and obsolete inventory reserves — (24,000 ) Less: consigned inventory reserves — (51,000 ) Inventories, net $ 454,379 $ 256,149 Consigned inventory represents products that have been delivered for which the Company has not met the criteria to recognize revenue. At December 31, 2018, the Company recorded consigned inventory and associated reserves for units that will not be sold based on historical experience. Consigned inventory and the associated reserves were reversed upon adoption of ASC 606 on January 1, 2019. See Note 3 – Summary of Significant Accounting Policies – Cost of Revenue.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 5 — Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices available in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The carrying amounts of the Company’s financial instruments such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents are a money market fund that limits its investments to only short-term U.S. Treasury securities and repurchase agreements related to these securities. Cash equivalents and derivative liabilities measured at fair value on a recurring basis at September 30, 2019 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2019 Total Cash equivalents $ 3,828,167 $ — $ — $ 3,828,167 Derivative liabilities $ — $ — $ 43,942 $ 43,942 The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the nine months ended September 30, 2019: Common stock warrant liability Balance – January 1, 2019 $ 3,661 Issuance of warrants 196,236 Change in fair value of derivative liabilities (155,955 ) Balance –September 30, 2019 $ 43,942 The expected stock price volatility for the Company’s common stock warrant liabilities was determined by the historical volatilities for industry peers and used an average of those volatilities. Risk free interest rates were obtained from U.S. Treasury rates for the applicable periods. The expected term used is the contractual life of the instrument being valued. The expected dividend yield was not considered in the valuation of the common stock liabilities as the Company has never paid, nor has the intention to pay, cash dividends.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Common Stock	Note 6 — Common Stock During the nine months ended September 30, 2019, the Company completed an underwritten public offering in which it sold 4,542,500 shares of its common stock generating net proceeds of approximately $5,604,000. In conjunction with the offering, the Company issued to the underwriter a warrant to purchase 363,400 shares of common stock at an exercise price of $1.75 per share. The fair value of the grant was included in the net proceeds from the public offering. During the nine months ended September 30, 2019, 9,928 stock options were exercised. During the nine months ended September 30, 2019, 27,940 shares of restricted stock vested and 159,182 (net of 55,506 shares withheld for employee taxes) of restricted stock units vested.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2019
Warrants And Rights Note Disclosure [Abstract]
Warrants	Note 7 — Warrants On June 9, 2017, the Company issued warrants for the purchase of 33,275 shares of common stock to its IPO selling agent (the “June 2017 Warrants”). The June 2017 Warrants became fully vested, exercisable on December 9, 2017 by the holder at an exercise price of $8.25 per share and have a life of five years. The June 2017 Warrants include a fundamental transaction clause which provide for the warrant holder to be paid in cash upon an event as defined in the warrant. The cash payment is to be computed using the Black-Scholes valuation model for the unexercised portion of the warrant. Accordingly, under ASC 815 Derivative and Hedging the June 2017 Warrants were deemed to be a derivative liability and are marked to market at each reporting period. On September 30, 2019 and December 31, 2018, the derivative liability was marked to its then fair value market value of approximately $300 and $3,700 respectively. Assumptions utilized in the valuation of the June 2017 Warrant, for the nine months ended September 30, 2019, were as follows: Risk-free interest rate 1.59% Expected life 2.69 Expected volatility of underlying stock 66.20% Expected dividend yield — On February 8, 2019, the Company issued warrants for the purchase of 363,400 shares of common stock to its February 2019 Offering selling agent (the “February 2019 Warrants”). The February 2019 Warrants are exercisable at any time after August 8, 2019 by the holder at an exercise price of $1.75 per share and have a life of four years. The warrants include a fundamental transaction clause that include transactions that may not require approval by the Company, such as a hostile tender offer. These transactions could require the Company to settle in cash upon exercise. Upon a fundamental transaction, the warrant holder would receive the equivalent securities or alternate considerations just prior to the triggering event by apportioning the exercise price among the equivalent securities. Assumptions utilized in the valuation of the February 2019 Warrant for the nine months ended September 30, 2019, were as follows: Risk-free interest rate 1.56% Expected life 3.36 Expected volatility of underlying stock 64.01% Expected dividend yield —

Stock Award Plans and Stock-bas

Stock Award Plans and Stock-based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plans and Stock-based Compensation	Note 8 — Stock Award Plans and Stock-based Compensation Stock Option Awards The Company uses the Black-Scholes option pricing model to estimate the grant date fair value of its stock options. There was no income tax benefit recognized in the financial statements for share-based compensation arrangements for the nine months ended September 30, 2019 and 2018. The assumptions underlying the calculation of grant date fair value per share are as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2019 2018 2019 2018 Number of options granted 4,500 41,000 181,000 278,000 Weighted-average expected volatility 63.45 % 60%-61% 62.56 % 60%-62% Weighted-average risk-free interest rate 1.90 % 2.73%-2.78% 2.16 % 2.73%-3.04% Weighted-average expected option term (in years) 6.25 6.25 6.46 6.25-9.92 Weighted-average dividend yield — % — % — % — % Weighted-average fair value per share of grants $ 0.46 $ 1.43 $ 0.64 $ 2.02 The stock price volatility for the Company’s options was determined using historical volatilities for industry peers. The risk-free interest rate was derived from U.S. Treasury rates existing on the date of grant for the applicable expected option term. The expected term represents the period of time that options are expected to be outstanding. Because the Company has only very limited historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. The expected dividend yield assumption is based on the fact that the Company has never paid, nor has any intention to pay, cash dividends. On June 19, 2018, the Company’s shareholders and the Board of Directors approved the Myomo, Inc. 2018 Stock Option and Incentive Plan (the “2018 Plan”). The number of shares of common stock available for awards under the 2018 Plan at inception was equal to 706,119 shares, which included the remaining 86,119 shares available for grant under the 2016 Plan on April 1, 2018. On January 1, 2019, the number of shares reserved and available for issuance under the 2018 Plan increased by 620,000 shares pursuant to a provision in the 2018 Plan that provides that the number of shares of common stock reserved and available for issuance under the 2018 Plan will be cumulatively increased each January 1, beginning on January 1, 2019, by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee. Awards of restricted stock units are often net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. These payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. Share-Based Compensation Expense The Company accounts for stock awards to employees and non-employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Prior to the adoption of ASU 2018-07 Compensation – Stock Compensation Improvement to Non-Employee Share-Based Payments The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period. The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees, restricted stock awards to employees and directors, and restricted stock units to employees, in the statements of operations as follow: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research and development $ 29,100 $ 24,241 $ 94,550 $ 77,528 Selling, general and administrative 117,851 126,640 645,754 565,433 Total $ 146,951 $ 150,881 $ 740,304 $ 642,961 As of September 30, 2019, there was approximately $288,600 As of September 30, 2019, there was approximately $61,500 of unrecognized compensation cost related to unvested restricted stock awards that is expected to be recognized over a weighted-average period of 1.20 years. As of September 30, 2019, there was approximately $323,200 unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 1.63 years.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 9 — Related Party Transactions The Company sells its products to an orthotics and prosthetics practice whose ownership includes an individual who is both a shareholder and executive officer of the Company. Sales to this related party are sold at standard list prices. During the nine months ended September 30, 2019 and 2018, revenue recognized on sales to this orthotics and prosthetics practice amounted to approximately $26,000 and $336,700, respectively. The Company also obtains consulting and fabrication services, reported in cost of goods sold, from the same related party. Charges for these services amounted to approximately $338,200 and $397,300

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 — Commitments and Contingencies Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Currently, there is no litigation against the Company. Major Customers For the nine months ended September 30, 2019, there were no individual customers who accounted for more than 10% of revenues. For the nine months ended September 30, 2018, one customer accounted for approximately 23% (related party) of revenues, excluding grant income. The Company sells its products to an orthotics and prosthetics practice whose ownership includes an individual who is both a minor shareholder and employee of the Company. At September 30, 2019, four customers accounted for approximately 24%, 19 At December 31, 2018, two customers accounted for approximately 20% and 16% of accounts receivable.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 11 — Subsequent Events On October 22, 2019, the Company entered into a Term Loan with Chicago Venture Partners . Under the Term Loan, the Company received gross proceeds of $3.0 million, excluding fees and expenses. Including an original issue discount, the Company will repay the Lender $3.3 million. The Term Loan bears interest at a rate of 10% and matures 18 months from the issuance date. Monthly redemptions of up to $300,000 begin six months from the closing date. The Lender has granted the Company an option to defer up to three redemption payments. If the Company elects to defer any payments, the Company will pay the Lender a fee that is the greater of (i) $35,000, or (ii) 1%, 1.25% and 1.5% of the outstanding balance for each deferral, respectively, which shall be added to the outstanding balance. The Term Loan is secured by all of the Company’s assets, excluding intellectual property. The Company has agreed that it will not pledge its intellectual property assets to any other party for so long as the Term Loan is outstanding. Subject to the terms and conditions set forth in the Term Loan, the Company may prepay all or any portion of the outstanding balance of the Term Loan, which includes accrued but unpaid interest, as well as collections and enforcement costs, transfer, stamp, issuance and similar taxes and fees incurred under the Term Loan, at any time subject to a prepayment penalty of 15% of the amount of the outstanding balance to be repaid. For so long as the Term Loan remains outstanding, the Company has agreed to pay the Lender 50% of the gross proceeds that it receives from the sale of the Company’s common stock or other equity (excluding sales of common stock under the Company’s at market sales agreement, dated as of July 2, 2018, with B. Riley FBR Inc), which payments will be applied towards and reduce the outstanding balance of the note. The Term Loan also contains penalty provisions in an event of default. Events of default are categorized between minor events and major events, with penalties of 5% and 15% of the outstanding balance, respectively for each occurrence. Penalties can be incurred for up to three separate events of default, but are capped at 25% of the outstanding balance immediately prior to the first occurrence of an event of default. Events of default include (i) the failure to repay the Term Loan at maturity; (ii) the failure to make monthly redemption payments; (iii) the failure to make timely filings to the SEC; (iv) the failure to obtain the Lender’s prior consent to enter into a fundamental transaction, and (v) conditions of insolvency, receivership and bankruptcy filings. After the occurrence of an event of default, interest on the Term Loan will accrue at a rate of 18% per annum, or such lesser rate as permitted under applicable law. As described in the Term Loan, upon the occurrence of certain events of default, the outstanding balance will become automatically due and payable, and upon the occurrence of other events of default, the Lender may declare the outstanding balance immediately due and payable at such time or at any time thereafter. The Term Loan includes provisions for technical covenants, but no financial covenants, and the Lender has the right to consent to any additional debt financing arrangements, including convertible debt financings. In connection with the Term Loan, the Company paid its placement agent a commission equal to 6% of the gross proceeds of the Term Loan. The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no other subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying unaudited condensed financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with GAAP for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2019 and for the nine months ended September 30, 2019 and 2018. The results of operations for the nine months ended September 30, 2019 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2019, or any other period. These condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2018 and 2017, and for the years then ended, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving inventory.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2019 and December 31, 2018. Restricted cash consists of cash deposited with a financial institution as collateral for Company employee credit cards. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed balance sheets that sum to the total of the same amounts shown in the condensed statements of cash flows. September 30, 2019 December 31, 2018 Cash and cash equivalents $ 4,328,355 $ 6,540,794 Restricted cash 75,000 75,000 Total cash, cash equivalents, and restricted cash $ 4,403,355 $ 6,615,794
Revenue Recognition	Revenue Recognition Adoption of ASC Topic 606, “Revenue from Contracts with Customers” On January 1, 2019, the Company adopted the new accounting standard ASC 606, “Revenue from Contracts with Customers” and all the related amendments (Topic 606) using the modified retrospective method for all contracts not completed as of the date of adoption. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with practical expedient ASC 606-10-65-1-(f)-4, which did not have a material effect on the Company’s assessment of the cumulative effect adjustment Revenues under Topic 606 are required to be recognized either at a “point in time” or “over time,” depending on the facts and circumstances of the arrangement, and are evaluated using a five-step model. The adoption of Topic 606 did not have a material impact on the financial statements at initial implementation. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin on an ongoing basis. The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract 3) Determination of the transaction price, including the constraint on variable consideration 4) Allocation of the transaction price to the performance obligations in the contract 5) Recognition of revenue when, or as, performance obligations are satisfied Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. In certain cases, the Company ships the MyoPro device to O&P providers or directly to patients pending reimbursement from third party payors. As a result of these arrangements, elements of the revenue recognition criteria have not been met upon shipment of the MyoPro. During the three and nine months ended September 30, 2019, the Company recognized revenue of approximately $164,000 from O&P providers or third party payors for which costs related to the completion of the Company’s performance obligations were recorded in a prior period. The Company periodically receives federally-funded grants that requires us to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. As required under Topic 606, grant proceeds are now booked as a reduction in R&D expenses. The Company adopted the accounting standard on a modified retrospective method, and the prior comparative 2018 grant revenue has not been restated for presentation purposes. Grant revenue was previously recognized when persuasive evidence of the arrangement existed, the service had been provided and adherence to specific parameters of the awarded grant were met, the amount was fixed and determinable and collection was reasonably assured. The Company recognized the revenue on a completion of performance basis where no ongoing obligation existed, or ratably over the term if the grant of no specific performance was required. Direct costs related to these grants were reported as a component of research and development costs in the statements of operations except for reimbursable costs which were reported as a component of cost of revenue in the statement of operations. The Company recognized approximately $10,100 and $19,100 of grant income in the three and nine months ended September 30, 2018. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Shipping and handling activities are not considered a contract performance obligation. The Company records shipping and handling costs billed to customers as revenue with offsetting costs recorded as cost of revenue. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had an immaterial amount of deferred revenue as of September 30, 2019. Disaggregated Revenue from Contracts with Customers The following table presents revenue by major source: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2019 2019 Clinical/Medical providers $ 405,914 $ 1,837,667 Direct to patient 200,705 479,367 Total revenue from contracts with customer $ 606,619 $ 2,317,034 Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third party payors. Prior to the implementation of ASC 606, the Company had been accounting for this transaction at the time of shipping to an O&P provider by leaving consigned inventory on the balance sheet until the uncertainty regarding payment had been resolved and by providing a consignment inventory reserve based upon the amounts historically collected under this program. Under ASC 340-40-25, this inventory is expensed as of the date of shipment. For clinical services by O&P providers for which they are paid a fee in conjunction with devices being sold directly to patients and billing their insurance companies directly, the cost of evaluations performed by the O&P providers are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense, with the remaining costs associated with the patient expensed to cost of revenue. The Company recorded a net decrease to opening retained earnings of approximately $123,000 as of January 1, 2019 due to the cumulative impact of adopting Topic 606. The cumulative effect of the changes made to the Company’s consolidated balance sheet for the adoption of Topic 606 were as follows: Selected Balance Sheet Accounts Balance at 12/31/18 Adjustments due to ASC 2014-09 Balance at 1/1/19 Assets Inventories, net $ 256,149 $ (84,635 ) $ 171,514 Prepaid expenses and other 695,276 (38,812 ) 656,464 Stockholders’ Equity Accumulated deficit (45,289,526 ) (123,447 ) (45,412,973 )
Net Loss per Share	Net Loss per Share Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three and nine months ended September 30, 2019 and 2018, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential common shares issuable consist of the following at: September 30, 2019 2018 Stock options 668,785 626,619 Restricted stock units 385,337 43,751 Restricted stock 10,266 48,707 Stock warrants 5,435,287 5,071,887 Total 6,499,675 5,790,964
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, or ASU 2016-02. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial statements. As an emerging growth company, the Company will delay adoption of ASU 2016-02 until January 1, 2020.
Subsequent Events	Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed in Note 11 herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed balance sheets that sum to the total of the same amounts shown in the condensed statements of cash flows. September 30, 2019 December 31, 2018 Cash and cash equivalents $ 4,328,355 $ 6,540,794 Restricted cash 75,000 75,000 Total cash, cash equivalents, and restricted cash $ 4,403,355 $ 6,615,794
Summary of Accounts Payable and Other Accrued Expenses	Accounts Payable and Other Accrued Expenses: September 30, 2019 December 31, 2018 Trade payables $ 346,493 $ 426,727 Accrued compensation and benefits 813,655 1,027,757 Accrued directors fees 23,750 — Accrued warranty costs 65,230 92,000 Accrued professional fees 102,233 44,660 Other 200,946 152,283 $ 1,552,307 $ 1,743,427
Summary of Revenue by Major Source	The following table presents revenue by major source: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2019 2019 Clinical/Medical providers $ 405,914 $ 1,837,667 Direct to patient 200,705 479,367 Total revenue from contracts with customer $ 606,619 $ 2,317,034
Summary of Potential Common Shares Issuable	Potential common shares issuable consist of the following at: September 30, 2019 2018 Stock options 668,785 626,619 Restricted stock units 385,337 43,751 Restricted stock 10,266 48,707 Stock warrants 5,435,287 5,071,887 Total 6,499,675 5,790,964
Adoption of ASC 606 [Member]
Cumulative Effect of Changes in Consolidated Balance Sheet for Adoption of Topic 606	The cumulative effect of the changes made to the Company’s consolidated balance sheet for the adoption of Topic 606 were as follows: Selected Balance Sheet Accounts Balance at 12/31/18 Adjustments due to ASC 2014-09 Balance at 1/1/19 Assets Inventories, net $ 256,149 $ (84,635 ) $ 171,514 Prepaid expenses and other 695,276 (38,812 ) 656,464 Stockholders’ Equity Accumulated deficit (45,289,526 ) (123,447 ) (45,412,973 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following at: September 30, 2019 December 31, 2018 Finished goods $ 35,165 $ 46,261 Consigned inventory — 135,635 Parts and components 419,214 149,253 454,379 331,149 Less: excess and obsolete inventory reserves — (24,000 ) Less: consigned inventory reserves — (51,000 ) Inventories, net $ 454,379 $ 256,149

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis	Cash equivalents and derivative liabilities measured at fair value on a recurring basis at September 30, 2019 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2019 Total Cash equivalents $ 3,828,167 $ — $ — $ 3,828,167 Derivative liabilities $ — $ — $ 43,942 $ 43,942
Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the nine months ended September 30, 2019: Common stock warrant liability Balance – January 1, 2019 $ 3,661 Issuance of warrants 196,236 Change in fair value of derivative liabilities (155,955 ) Balance –September 30, 2019 $ 43,942

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the nine months ended September 30, 2019: Common stock warrant liability Balance – January 1, 2019 $ 3,661 Issuance of warrants 196,236 Change in fair value of derivative liabilities (155,955 ) Balance –September 30, 2019 $ 43,942
Warrant
Class Of Warrant Or Right [Line Items]
Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured	Assumptions utilized in the valuation of the June 2017 Warrant, for the nine months ended September 30, 2019, were as follows: Risk-free interest rate 1.59% Expected life 2.69 Expected volatility of underlying stock 66.20% Expected dividend yield — Assumptions utilized in the valuation of the February 2019 Warrant for the nine months ended September 30, 2019, were as follows: Risk-free interest rate 1.56% Expected life 3.36 Expected volatility of underlying stock 64.01% Expected dividend yield —

Stock Award Plans and Stock-b_2

Stock Award Plans and Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Grant Date Fair Value	The assumptions underlying the calculation of grant date fair value per share are as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2019 2018 2019 2018 Number of options granted 4,500 41,000 181,000 278,000 Weighted-average expected volatility 63.45 % 60%-61% 62.56 % 60%-62% Weighted-average risk-free interest rate 1.90 % 2.73%-2.78% 2.16 % 2.73%-3.04% Weighted-average expected option term (in years) 6.25 6.25 6.46 6.25-9.92 Weighted-average dividend yield — % — % — % — % Weighted-average fair value per share of grants $ 0.46 $ 1.43 $ 0.64 $ 2.02
Schedule of Stock-based Compensation Expense	The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees, restricted stock awards to employees and directors, and restricted stock units to employees, in the statements of operations as follow: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research and development $ 29,100 $ 24,241 $ 94,550 $ 77,528 Selling, general and administrative 117,851 126,640 645,754 565,433 Total $ 146,951 $ 150,881 $ 740,304 $ 642,961

Going Concern and Management'_2

Going Concern and Management's Plan - Additional Information (Detail) - USD ($)	Oct. 22, 2019	Feb. 28, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Dec. 31, 2018
Going Concern and Managements Liquidity Plan [Line Items]
Net loss			$ 2,788,118	$ 2,565,327	$ 2,598,060	$ 2,649,822	$ 2,629,561	$ 2,345,402	$ 7,951,505	$ 7,624,785
Accumulated deficit			$ 53,364,478						53,364,478		$ 45,412,973	$ 45,289,526
Cash used in operating activities									$ 7,697,702	$ 7,093,299
Proceeds from FPO, net of offering costs		$ 5,600,000
Subsequent Event [Member] | Chicago Venture Partners [Member] | Term Loan [Member]
Going Concern and Managements Liquidity Plan [Line Items]
Proceeds from term loan	$ 3,000,000
Proposed repayment of term loan including original issue discount	$ 3,300,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 4,328,355	$ 6,540,794
Restricted cash	75,000	75,000
Total cash, cash equivalents, and restricted cash	$ 4,403,355	$ 6,615,794	$ 9,168,412	$ 13,011,373

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Accounts Payable and Other Accrued Expenses (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Trade payables	$ 346,493	$ 426,727
Accrued compensation and benefits	813,655	1,027,757
Accrued directors fees	23,750
Accrued warranty costs	65,230	92,000
Accrued professional fees	102,233	44,660
Other	200,946	152,283
Total	$ 1,552,307	$ 1,743,427

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Adoption of ASC 606 [Member]
Summary of Significant Accounting Policies [Line Items]
Cumulative adjustment to equity	$ 123,000		$ 123,000
Grant Income [Member]
Summary of Significant Accounting Policies [Line Items]
Grant income recognized		$ 10,100		$ 19,100
O&P Providers or Third Party Payors [Member]
Summary of Significant Accounting Policies [Line Items]
Revenue recognized	$ 164,000		$ 164,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	$ 606,619	$ 608,981	$ 2,317,034	$ 1,554,529
Clinical/Medical Providers [Member]
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	405,914		1,837,667
Direct to Patient [Member]
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	$ 200,705		$ 479,367

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Cumulative Effect of Changes in Consolidated Balance Sheet for Adoption of Topic 606 (Detail) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
ASSETS
Inventories, net	$ 454,379	$ 171,514	$ 256,149
Prepaid expenses and other	786,732	656,464	695,276
Stockholders’ Equity:
Accumulated deficit	$ (53,364,478)	(45,412,973)	(45,289,526)
Adoption of ASC 606 [Member] | Balance [Member]
ASSETS
Inventories, net			256,149
Prepaid expenses and other			695,276
Stockholders’ Equity:
Accumulated deficit			$ (45,289,526)
Adoption of ASC 606 [Member] | Adjustments due to ASC 2014-09
ASSETS
Inventories, net		(84,635)
Prepaid expenses and other		(38,812)
Stockholders’ Equity:
Accumulated deficit		$ (123,447)

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,499,675	5,790,964
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	385,337	43,751
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,266	48,707
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	668,785	626,619
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,435,287	5,071,887

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished goods	$ 35,165		$ 46,261
Consigned inventory			135,635
Parts and components	419,214		149,253
Total cost	454,379		331,149
Less: excess and obsolete inventory reserves			(24,000)
Less: consigned inventory reserves			(51,000)
Inventories, net	$ 454,379	$ 171,514	$ 256,149

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 3,828,167
Derivative liabilities	43,942	$ 3,661
In Active Markets for Identical Assets or Liabilities (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	3,828,167
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	$ 43,942

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured (Detail)	9 Months Ended
	Sep. 30, 2019USD ($)
Fair Value Disclosures [Abstract]
Beginning balance	$ 3,661
Issuance of warrants	196,236
Change in fair value of derivative liabilities	(155,955)
Ending balance	$ 43,942

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended
	Feb. 28, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019
Class of Stock [Line Items]
Net proceeds from issuance of common stock	$ 5,600,000
Stock options exercised								9,928
Net withheld for employee taxes		3,015	7,032	45,459	1,653	1,692	17,570
Underwritten Public Offering [Member]
Class of Stock [Line Items]
Proceeds from offering costs, shares								4,542,500
Net proceeds from issuance of common stock								$ 5,604,000
Underwriter Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		363,400						363,400
Common stock warrants, exercise price per share		$ 1.75						$ 1.75
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, Vested								27,940
Restricted Stock Units [Member]
Class of Stock [Line Items]
Number of shares, Vested								159,182
Net withheld for employee taxes								55,506

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($)	Feb. 08, 2019	Jun. 09, 2017	Sep. 30, 2019	Dec. 31, 2018
June 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants are fully vested, exercise price		$ 8.25
Fair value of the warrants derivative liability			$ 300	$ 3,700
June 2017 Warrants [Member] | IPO Selling Agent [Member]
Class Of Warrant Or Right [Line Items]
Purchase of warrants issued		33,275
June 2017 Warrants [Member] | IPO [Member]
Class Of Warrant Or Right [Line Items]
Warrants years of life		5 years
February 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants are fully vested, exercise price	$ 1.75
Fair value of the warrants derivative liability	$ 196,000		$ 43,600
February 2019 Warrants [Member] | IPO Selling Agent [Member]
Class Of Warrant Or Right [Line Items]
Purchase of warrants issued	363,400
February 2019 Warrants [Member] | IPO [Member]
Class Of Warrant Or Right [Line Items]
Warrants years of life	4 years

Warrants - Schedule of Assumpti

Warrants - Schedule of Assumptions Utilized in the Valuation of Warrant (Detail)	Sep. 30, 2019yr
Risk-free Interest Rate [Member] | June 2017 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0.0159
Risk-free Interest Rate [Member] | February 2019 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0.0156
Expected Life [Member] | June 2017 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	2.69
Expected Life [Member] | February 2019 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	3.36
Expected Volatility of Underlying Stock [Member] | June 2017 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0.6620
Expected Volatility of Underlying Stock [Member] | February 2019 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0.6401
Expected Dividend Yield [Member] | June 2017 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0
Expected Dividend Yield [Member] | February 2019 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0

Stock Award Plans and Stock-b_3

Stock Award Plans and Stock-based Compensation - Additional Information (Detail) - USD ($)	Jun. 19, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Apr. 01, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit recognized		$ 0	$ 0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 288,600
Weighted-average remaining contractual term		2 years 5 months 23 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 61,500
Weighted-average remaining contractual term		1 year 2 months 12 days
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 323,200
Weighted-average remaining contractual term		1 year 7 months 17 days
2018 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant	706,119
Number of common shares reserved for issuance				620,000
Percentage increase in number of shares of common stock reserved and available for issuance	4.00%
2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant					86,119

Stock Award Plans and Stock-b_4

Stock Award Plans and Stock-based Compensation - Schedule of Grant Date Fair Value (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Option Indexed to Issuer's Equity [Line Items]
Number of options granted	4,500	41,000	181,000	278,000
Weighted-average expected volatility	63.45%		62.56%
Weighted-average risk-free interest rate	1.90%		2.16%
Weighted-average expected option term (in years)	6 years 3 months	6 years 3 months	6 years 5 months 15 days
Weighted-average fair value per share of grants	$ 0.46	$ 1.43	$ 0.64	$ 2.02
Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Weighted-average expected volatility		60.00%		60.00%
Weighted-average risk-free interest rate		2.73%		2.73%
Weighted-average expected option term (in years)				6 years 3 months
Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Weighted-average expected volatility		61.00%		62.00%
Weighted-average risk-free interest rate		2.78%		3.04%
Weighted-average expected option term (in years)				9 years 11 months 1 day

Stock Award Plans and Stock-b_5

Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 146,951	$ 150,881	$ 740,304	$ 642,961
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	29,100	24,241	94,550	77,528
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 117,851	$ 126,640	$ 645,754	$ 565,433

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Related Party Transactions [Abstract]
Revenue recognized from related party	$ 26,000	$ 336,700
Due from related party	0		$ 0
Charges for services	338,200	$ 397,300
Accounts payable and accrued expenses	$ 49,200		$ 54,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Customer	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Number of customers	0	1
Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Number of customers	4		2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Due From Related Party [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		23.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	24.00%		20.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	19.00%		16.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	19.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage	19.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - Chicago Venture Partners [Member] - Term Loan [Member]	Oct. 22, 2019USD ($)Payment
Subsequent Event [Line Items]
Proceeds from term loan	$ 3,000,000
Proposed repayment of term loan including original issue discount	$ 3,300,000
Term loan, interest rate	10.00%
Term loan, maturity period	18 months
Debt instrument first defer redemption payment, fee percentage	1.00%
Debt instrument second defer redemption payment, fee percentage	1.25%
Debt instrument third defer redemption payment, fee percentage	1.50%
Rate of penalty prepayment of outstanding balance of term loan	15.00%
Percentage of term loan payment on gross proceeds from sale of common stock or other equity	50.00%
Debt instrument, Minor event of default penalty rate	5.00%
Debt instrument, Major event of default penalty rate	15.00%
Debt instrument, default penalty capped rate	25.00%
Percentage of payment of placement agent commission	6.00%
Maximum [Member]
Subsequent Event [Line Items]
Amount of monthly redemption of term loan	$ 300,000
Number of options granted for deferred redemption payments | Payment	3
Debt instrument, defer redemption payments fee	$ 35,000
Interest on term loan accrued,after default	18.00%